Recently, the Class 1 innovative drug Rezivertinib Mesylate Capsules (trade name: 瑞必达) of Beta Pharma (Shanghai) Co., Ltd. is approved for marketing by China NMPA. This drug is indicated for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression on or after prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and have been confirmed to have an EGFR T790M mutation.

Rezivertinib Mesylate is an epidermal growth factor receptor (EGFR) kinase inhibitor that irreversibly inhibits EGFR mutants (e.g., EGFR T790M, L858R). The marketing of this drug provides new treatment options for adult patients with non-small cell lung cancer.